Drug Profile
hTERT-derived peptide vaccine - Invectys
Alternative Names: Human telomerase reverse transcriptase peptide-based vaccine - Invectys; UCP2-UCP4 vaccine - Invectys; UCPVaxLatest Information Update: 04 Jul 2023
Price :
$50
*
At a glance
- Originator Invectys
- Developer Institut Pasteur; Regional and University Hospital of Besancon
- Class Cancer vaccines; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Non-small cell lung cancer
- Phase I/II Glioblastoma
Most Recent Events
- 02 Jun 2023 Efficacy and adverse events data from a phase I/II trial in Glioblastoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 07 Dec 2022 hTERT-derived peptide vaccine is still in phase II trials for in Non-small c ell lung cancer France (NCT04263051)
- 09 Sep 2020 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater, Combination therapy) in France (SC) (NCT04263051)